The stock of NovoCure Limited (NASDAQ:NVCR) is a huge mover today! The stock increased 4.94% or $0.95 during the last trading session, reaching $20.2. About 359,136 shares traded. NovoCure Limited (NASDAQ:NVCR) has declined 0.43% since December 1, 2016 and is downtrending. It has underperformed by 17.13% the S&P500.The move comes after 6 months positive chart setup for the $1.81 billion company. It was reported on Dec, 1 by Barchart.com. We have $22.02 PT which if reached, will make NASDAQ:NVCR worth $162.45 million more.
The stock increased 0.38% or $0.04 during the last trading session, reaching $9.78. About 36,673 shares traded. BlackRock MuniVest Fund, Inc. (MVF) has declined 10.07% since December 1, 2016 and is downtrending. It has underperformed by 26.77% the S&P500.
Analysts await NovoCure Limited (NASDAQ:NVCR) to report earnings on February, 22. They expect $-0.15 earnings per share, up 42.31% or $0.11 from last year’s $-0.26 per share. After $-0.13 actual earnings per share reported by NovoCure Limited for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.
Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. Wedbush maintained NovoCure Limited (NASDAQ:NVCR) rating on Friday, July 29. Wedbush has “Outperform” rating and $20 target. As per Tuesday, October 27, the company rating was initiated by Wedbush. JP Morgan initiated the shares of NVCR in report on Tuesday, October 27 with “Overweight” rating. The rating was initiated by Barclays Capital on Tuesday, January 19 with “Underweight”. Deutsche Bank initiated the stock with “Hold” rating in Wednesday, December 2 report. The firm has “Market Outperform” rating given on Tuesday, October 27 by JMP Securities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.